ReviewOxidative medicine and cellular longevity2022
Intermittent Hypoxia and Atherosclerosis: From Molecular Mechanisms to the Therapeutic Treatment.
Review in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Associations Between the Severity of Obstructive Sleep Apnea and Arterial Stiffness Estimated by Pulse Wave Velocity Assessment: A Cross-Sectional Study.Health science reports · 2026Article
- Exosomal lncRNA ENST00000592016 rescues the Weakened Viability of HUVEC Cells Caused by Intermittent Hypoxia.Combinatorial chemistry & high throughput screening · 2026Article
- Causal relationship between obstructive sleep apnea and diabetic nephropathy: bidirectional and multivariable Mendelian randomization study.Renal failure · 2025Article
- Risk assessment and prevention of cardiovascular events in patients with obstructive sleep apnea syndrome: A narrative review.International journal of cardiology. Cardiovascular risk and prevention · 2025Review
- Article
- Retracted: Intermittent Hypoxia and Atherosclerosis: From Molecular Mechanisms to the Therapeutic Treatment.Oxidative medicine and cellular longevity · 2024Article
- Exploring shared pathways and the shared biomarker ERRFI1 in Obstructive sleep apnoea and atherosclerosis using integrated bioinformatics analysis.Scientific reports · 2023Article
- Identification and validation of potential hypoxia-related genes associated with coronary artery disease.Frontiers in physiology · 2023Article
- Continuous Hypobaric Hypoxia may Promote Atherosclerosis Progression in Apolipoprotein E-deficient Mice.International journal of medical sciences · 2023Article
- Danlou Tablet May Alleviate Vascular Injury Caused by Chronic Intermittent Hypoxia through Regulating FIH-1, HIF-1, and Angptl4.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
- Retraction · 2024-01-09Compromised Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intermittent hypoxia (IH) has a dual nature. On the one hand, chronic IH (CIH) is an important pathologic feature of obstructive sleep apnea (OSA) syndrome (OSAS), and many studies have confirmed that OSA-related CIH (OSA-CIH) has atherogenic effects involving complex and interacting mechanisms. Limited preventive and treatment methods are currently available for this condition. On the other hand, non-OSA-related IH has beneficial or detrimental effects on the body, depending on the degree, duration, and cyclic cycle of hypoxia. It includes two main states: intermittent hypoxia in a simulated plateau environment and intermittent hypoxia in a normobaric environment. In this paper, we compare the two types of IH and summarizes the pathologic mechanisms and research advances in the treatment of OSA-CIH-induced atherosclerosis (AS), to provide evidence for the systematic prevention and treatment of OSAS-related AS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.